| Target Price | HK$8.36 |
| Price | HK$5.35 |
| Potential |
56.34%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Ocumension Therapeutics 2027 .
The average Ocumension Therapeutics target price is HK$8.36.
This is
56.34%
register free of charge
HK$8.90
66.43%
register free of charge
HK$8.00
49.52%
register free of charge
|
|
| A rating was issued by 8 analysts: 6 Analysts recommend Ocumension Therapeutics to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ocumension Therapeutics stock has an average upside potential 2027 of
56.34%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million HK$ | 940.84 | 1,294.84 |
| 92.75% | 37.63% | |
| EBITDA Margin | -19.15% | 10.50% |
| 71.32% | 154.82% | |
| Net Margin | -19.75% | 3.01% |
| 69.29% | 115.24% |
4 Analysts have issued a sales forecast Ocumension Therapeutics 2026 . The average Ocumension Therapeutics sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Ocumension Therapeutics EBITDA forecast 2026. The average Ocumension Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Ocumension Therapeutics Analysts have issued a net profit forecast 2026. The average Ocumension Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | -0.23 | 0.05 |
| 50.00% | 121.74% | |
| P/E | 110.64 | |
| EV/Sales | 3.04 |
4 Analysts have issued a Ocumension Therapeutics forecast for earnings per share. The average Ocumension Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Ocumension Therapeutics...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


